FDA approves another generic of abortion pill mifepristone| STAT

The Food and Drug Administration has recently approved another generic version of the abortion pill mifepristone, a decision that has sparked criticism from anti-abortion groups and politicians with ties to the Trump administration. Evita Solutions, the drugmaker behind the low-cost generic pill, announced the FDA’s approval on its website, marking a significant development in reproductive health.

The approval of this generic version has been met with backlash from groups like Students for Life Action, who called it “a stain on the Trump presidency,” and Republican Senator Josh Hawley, who expressed his lack of confidence in the FDA’s leadership. Despite the criticism, the FDA maintains that its role in approving generic drugs is limited, and officials do not endorse specific products.

This move comes amidst pressure from abortion opponents for a reevaluation of mifepristone, a drug that has been deemed safe and effective by FDA scientists for the past 25 years. The original version of mifepristone was approved in 2000, with access gradually expanding over time. In 2021, the FDA under President Joe Biden permitted online prescribing and mail-order delivery of the drug, a decision that has faced opposition from anti-abortion groups.

Generic drug approval is a routine process at the FDA, with companies typically required to demonstrate that their drug matches the original formula. Evita Solutions filed its application for the generic mifepristone four years ago, and the approval process typically takes around 10 months. The company has emphasized its commitment to providing safe and affordable abortion care on its website.

The availability of generic mifepristone is unlikely to impact access to the pill, which is often used in combination with misoprostol for abortions up to 10 weeks. However, restrictions on the pill exist in many states due to laws that ban or impose limitations on medication abortion. These laws are currently the subject of ongoing lawsuits in the legal system.

Despite the controversy surrounding mifepristone, major medical societies like the American Medical Association do not support restrictions on the drug. The approval of the generic version represents a step forward in reproductive health care access, but the debate over abortion rights and access to medication abortion continues to be a contentious issue in the United States.